Charlotte's Web co-founder Jared Stanley resigns from board to focus on DeFloria Phase 2 drug
Charlotte's Web Holdings, Inc.
Co-founder Jared Stanley resigned from Board on June 3, 2026 to become CEO of DeFloria, advancing its FDA Phase 2 botanical drug for autism irritability.
Charlotte's Web co-founded DeFloria in 2023 with AJNA BioSciences; DeFloria is developing AJA001 oral solution for autism irritability.
Stanley will remain as advisor to Charlotte's Web and continue as ONE HEMP representative.
Board size reduced to six directors following Stanley's resignation.
Departure not due to any disagreement with management or operations per company statement.
On June 3, 2026, Mr. Jared Stanley notified Charlotte’s Web Holdings, Inc. (the “Company”) of his intention to resign from his position as a member of the Board of Directors of the Company (and any committees upon which he sits) effective as of June 3, 2026.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Jared Stanley resigned as Member of the Board of Directors at Charlotte's Web Holdings, Inc..
Action
resigned
Role
Member of the Board of Directors
Exact text from the filing
On June 3, 2026, Mr. Jared Stanley notified Charlotte’s Web Holdings, Inc. (the “Company”) of his intention to resign from his position as a member of the Board of Directors of the Company (and any committees upon which he sits) effective as of June 3, 2026.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.